Lay Title: Combination immunotherapy in patients with metastatic urothelial cancer previously treated with platinum based chemotherapy
Technical Title: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Failure with Platinum Containing Chemotherapy (MORPHEUS-mUC)
Disease Type: Metastatic Urothelial cancer
Basic information: The purpose of this study is to offer combination immunotherapies after platinum failure in patients with metastatic urothelial cancer
Research Procedures (not a complete list): More details upon entering study will be provided in terms of biopsy requirements and treatment schedule.
Eligibility Criteria (not a complete list):
a.Subjects that received neoadjuvant chemotherapy with recurrence <12 months from completion of therapy are permitted.
b.Subjects that received adjuvant chemotherapy following cystectomy with recurrence <12 months from completion of therapy are permitted
For More Detailed Information, Contact:
ClinicalTrials.gov Identifier: NCT03869190